ApicHope(SZ:300723) Zheng Quan Shi Bao Wang·2025-10-29 11:36Core Viewpoint - Yipinhong (300723) reported a narrowing loss in its Q3 2025 financial results, with revenue of 814 million yuan and a net loss of 136 million yuan for the first three quarters, reflecting a year-on-year reduction in loss by 44.80% [1] Financial Performance - For Q3 2025, the company achieved revenue of 230 million yuan and a net loss of 62.54 million yuan, with the loss narrowing by 78.65% year-on-year [1] - Cumulatively, the company’s revenue for the first three quarters reached 814 million yuan, with a net loss of 136 million yuan [1] Product Development - As of the report date, Yipinhong received 16 drug registration approvals for 15 products, enhancing its product pipeline and core competitiveness [1] - The company’s innovative drug AR882, aimed at treating gout and gout stones, completed patient enrollment for its global Phase III trial, marking significant progress in its global development [1] - The company’s self-developed innovative drug APH03621 has been approved for clinical trials targeting endometriosis [2] Mechanism and Clinical Results - APH03621 is a new oral, non-peptide small molecule GnRH receptor antagonist, which regulates the hypothalamic-pituitary-gonadal axis to treat endometriosis [2] - AR882 is a highly selective URAT1 inhibitor currently in Phase III clinical development for gout and gout stones, showing promising results in reducing serum uric acid levels and dissolving gout stones in patients [3] - Clinical findings indicate that AR882, either as monotherapy or in combination with allopurinol, effectively lowers sUA and reduces urate crystal burden, providing a more effective treatment option for chronic gout stone patients [3]